Current Treatments in Marginal Zone Lymphoma

Area of Science:

• Hematology
• Oncology
• Lymphoma Research

Background:

• Marginal zone lymphoma (MZL) encompasses heterogeneous indolent non-Hodgkin lymphomas (NHLs) with distinct subtypes: extranodal, splenic, and nodal.
• MZL accounts for 7% of mature NHLs, showing geographic incidence variations and links to infectious agents.
• Current treatment strategies often lack subtype specificity and are based on limited clinical trial data, necessitating updated approaches.

Purpose of the Study:

• To provide an updated analysis of the literature on Marginal Zone Lymphoma (MZL).
• To discuss current approaches to the diagnosis and treatment of MZL subtypes.
• To highlight recent advances, unmet needs, and future directions in MZL management.

Main Methods:

• Comprehensive literature review of recent findings in MZL diagnosis and treatment.
• Analysis of current risk stratification, therapeutic approaches, and clinical trial limitations.
• Discussion of emerging novel agents and their efficacy and safety profiles.

Main Results:

• Recent findings offer improved risk stratification but are not yet integrated into treatment decisions.
• Limited enrollment in randomized clinical trials for MZL subtypes hinders efficacy assessment.
• Novel agents show promise for improved efficacy and safety in MZL treatment.

Conclusions:

• Despite advances, significant unmet needs persist in MZL, including prognostic biomarkers and optimal therapy sequencing.
• There is a critical need for well-designed clinical trials to establish standard therapies and evaluate patient-reported outcomes.
• An updated understanding of MZL biology and treatment is essential for optimizing patient care.